Interleukin-22 Might Act as a Double-Edged Sword in Type 2 Diabetes and Coronary Artery Disease

Figure 7

Treatment with IL-22R1 antibody ameliorated the protective role of IL-22 in LPC-, glucose-, or combination-treated HUVECs. Cells were treated with LPC (10 μg/mL), glucose (30 mM), or a combination of the two (10 μg/mL LPC + 30 mM glucose) for 12 h followed by incubation with 40 ng/mL IL-22 or 0.8 μg/mL IL-22R1 antibody + 40 ng/mL IL-22 for 24 h. IL-22R1 antibody (8 μg/mL) was added 1 h before treatment with 40 ng/mL IL-22. The apoptotic rate was quantified by flow cytometry. Data shown represent mean ± SEM of three independent experiments. versus control group; versus control group. versus IL-22-treated group; versus IL-22 treated group; versus IL-22 treated group.

(a)

(b)

(c)